Clinical Trial

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated December 18, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06503094
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd, Zhujiang Hospital, Jingzhou Central Hospital, Shiyan People's Hospital, Xiangyang Central Hospital, Yichang Central People's Hospital
Conditions B-Cell Lymphoblastic Leukemia/Lymphoma
Enrollment 80 participants
Start Date 2024-01-14
Primary Completion 2025-12-18 (estimated)
Study Completion 2026-06-18 (estimated)
Updated on ClinicalTrials.gov 2024-07-16